Drug Search Results
Using advanced filters...
Advanced Search [+]

Degarelix

Alternative Names: degarelix, firmagon, asp-3550, asp3550, asp 3550
Clinical Status: Inactive
Latest Update: 2025-05-21
Latest Update Note: Clinical Trial Update

Product Description

Degarelix injection is used to treat advanced prostate cancer (cancer that begins in the prostate [a male reproductive gland]). Degarelix injection is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. This may slow or stop the spread of prostate cancer cells that need testosterone to grow. (Sourced from: https://medlineplus.gov/druginfo/meds/a609022.html)

Mechanisms of Action: GnRH Antagonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Ferring
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Degarelix

Countries in Clinic: Belgium, Canada, France, United States

Active Clinical Trial Count: 12

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Adenocarcinoma|Prostate Cancer

Phase 2: Male Breast Cancer

Phase 1: Bladder Cancer|Transitional Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

TASUC-Neo

P1

Recruiting

Bladder Cancer|Transitional Cell Carcinoma

2027-01-01

2025-03-22

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

GUIDANCE

P3

Recruiting

Adenocarcinoma|Prostate Cancer

2026-11-11

2025-03-18

Primary Endpoints

ETHAN

P2

Recruiting

Male Breast Cancer

2026-04-01

12%

2025-02-07

Primary Endpoints|Treatments

AFT-19

P3

Active, not recruiting

Prostate Cancer

2025-07-01

28%

2024-08-08

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

PREDICT-RT*

P3

Recruiting

Adenocarcinoma|Prostate Cancer

2033-12-31

2025-03-08

Primary Endpoints

S65935

P3

Recruiting

Prostate Cancer

2032-06-01

2025-05-02

Treatments

SChLAP/IDC

P2

Not yet recruiting

Prostate Cancer

2028-12-01

63%

2024-01-25

Primary Endpoints|Start Date|Treatments

MCC-21139

P2

Active, not recruiting

Prostate Cancer

2027-07-15

12%

2024-07-24

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

CAAA802A12101

P2

Recruiting

Prostate Cancer

2026-08-01

2025-05-02

Treatments

Neo-Red-P

P1

Active, not recruiting

Prostate Cancer

2025-06-01

4%

2024-07-10

Pro00061532

P2

Active, not recruiting

Prostate Cancer|Adenocarcinoma

2024-09-30

41%

2024-09-20

2016-002854-19

P2

Active, not recruiting

Prostate Cancer

2023-02-03

2022-03-13

Treatments